Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| So I think we continue to feel confident that our team on China particularly now with two distribution partners, we're well-positioned to continue to see growth in that part of the world particularly in China |
| Our expanded hybrid infrastructure in China, with over 80 in-country STAAR employees responsible for demand generation, will allow for improved customer service, including more real-time and next-day availability of our lenses |
| So, we feel very good about where we're at the resetting that we did this year and where we're going forward |
| With that as a backdrop, I am pleased to report that we delivered strong net sales, cash generation and profitability in 2023 |
| We were very pleased with the economics that we're negotiating those deals |
| We are growing profitably with high gross margins, and we have the ability to continue to drive higher operating margins |
| So, we're we just feel we're well-positioned |
| But pleased with what's happening in China, pleased with what's happening in the U.S., Europe has some nice momentum |
| Our strong financial position allows us to execute against this opportunity through the business cycle |
| Listen I feel very good about how the year has started |
| Our APAC and EMEA regions, up 26% and 18%, respectively, drove ICL sales growth in the quarter |
| EMEA, up 9% sequentially in the fourth quarter, generated solid growth, demonstrating the geographic breadth and diversification of STAAR's business |
| STAAR's geographic diversity provides a strong underpinning for refractive procedure growth and expands the target market for EVO procedures |
| But I think we feel good about pricing |
| We anticipate that APAC, including China and India, will remain a region of remarkable growth for STAAR as the ICL continues to take market share and expand the overall addressable market |
| And in fact we believe as we move forward over the next several years, there could be some upside to that from efficiencies within our manufacturing as well as more opportunities with economics across many markets that we're in right today |
| We have good leadership for the U.S |
| And I think people are recognizing that EVO ICL is not only better medicine by the outcomes that we're producing, but it can be better business |
| So, that has contemplated that as we penetrate markets like the US, which is still less than 10% of our revenue overall, that there would be some reduction in ASP, mostly related to just higher volume, right? And so, we still feel very good about maintaining that 80% as we go forward |
| And we continue to feel good about how the year has started for us |
| And we think we're very well-positioned as a -- and have first-mover advantage with nearly three million implants completed that be safety, the efficacy of our technology is very well-established particularly in that part of the world |
| STAAR and SharpeVision see this as a great win-win opportunity and we believe it is a model we can continue to leverage as we drive growth in the U.S |
| I think in terms of the Lunar New Year and how China has been going so far again as I've mentioned earlier, very encouraged by the start of the year |
| The equally thing that encouraged me is the spending that went on in that marketplace associated with the Lunar New Year was very encouraging from an overall economy point of view |
| So certainly, the momentum is shifting and we feel very good about how we're positioned |
| And just getting our infrastructure set up with this global training initiative, we're doing around clinical and practice development and sales to really have that really best-in-class combined with all the other efforts we're doing, we just believe we're surrounding the customer appropriately to make this a very predictable a very routine procedure |
| So in the end of the day, we think that's very, very positive |
| So I think both coexist nicely and really continue to position STAAR Surgical in the EVO ICL for future growth |
| I think their depth and breadth will help us continue to gain share and grow our business in China particularly as we mentioned in our prepared remarks in Tier 3 and Tier 4 cities |
| And the model is built so that if we do exceed or come in at the high end of our guidance or even go over that that you'll see that incremental dollar translate to the bottom-line quite strongly as it historically has |
| Statement |
|---|
| I think look at -- there's still uncertainty out in the world, macro headwinds |
| I think in the fourth quarter, the market research isn't out yet but it would suggest that it was about 20% down in many of the US practices in the fourth quarter |
| Obviously, a chunk of selling and marketing incremental dollars year-on-year driving some of that margin down |
| So market was significantly down and us being up 14%, 15% in the US again outpacing that market |
| So I think the trend is continuing to be a deceleration of refractive procedures, which in a certain way is just the inverse for us because we continue to outpace the market |
| As a reminder, Q1 and Q4 have historically represented our seasonally lowest quarters |
| And that's after up through the first three quarters anywhere from 9% to 15% down |
| It was a real deceleration |
| They won't have a toric offering that's certainly going to limit their attractiveness to the marketplace |
| I'd say around the world places like China in 2023 you saw a nice first half growth and then a deceleration in the second half that brought it back down to mid-single-digit growth overall |
| And we think it's going to be a slow ramp-up in the first half of China in 2024 and maybe get back to mid single digits to 10% in the back half of the year |
| And as that all comes together, price becomes a component, but it's not the driving component to a successful practice |
Please consider a small donation if you think this website provides you with relevant information